EICHOR
● Completed
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Condition: Hypertension · Sponsor: Novartis Pharmaceuticals
About this study
This is a single arm, multicenter, observational study to evaluate the safety and efficacy of Entresto Tablets during the first 52 weeks of treatment in Japanese patients with hypertension.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (117)
| Novartis Investigative Site | Anjo, Aichi-ken, Japan | — |
| Novartis Investigative Site | Ichinomiya, Aichi-ken, Japan | — |
| Novartis Investigative Site | Kasugai, Aichi-ken, Japan | — |
| Novartis Investigative Site | Nagoya, Aichi-ken, Japan | — |
| Novartis Investigative Site | Okazaki, Aichi-ken, Japan | — |
| Novartis Investigative Site | Ōbu, Aichi-ken, Japan | — |
| Novartis Investigative Site | Toyohashi, Aichi-ken, Japan | — |
| Novartis Investigative Site | Yatomi, Aichi-ken, Japan | — |
| Novartis Investigative Site | Inzai, Chiba, Japan | — |
| Novartis Investigative Site | Matsudo, Chiba, Japan | — |
| Novartis Investigative Site | Sakura, Chiba, Japan | — |
| Novartis Investigative Site | Yotsukaidō, Chiba, Japan | — |
+ 105 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05976230